Table 4 Serum metabolites associated with carotid atherosclerosis in the nonobese and obese MAFLD patients
Factors | Nonobese MAFLD | Obese MAFLD | ||
|---|---|---|---|---|
Univariate | Univariate | |||
OR (95%CI) | P | OR (95%CI) | P | |
Male | 0.99 (0.31–3.20) | 0.99 | 1.71 (0.34–8.69) | 0.52 |
Age increased per 10 years | 0.95 (0.67–1.34) | 0.76 | 3.32 (1.57–4.85) | < 0.001 |
Body mass index | 1.02 (0.78–1.34) | 0.88 | 1.03 (0.95–1.11) | 0.46 |
Increased WC | 0.98 (0.90–1.08) | 0.76 | 1.03 (0.97–1.12) | 0.56 |
Hypertension | 1.02 (0.98–1.05) | 0.32 | 1.01 (0.98–1.04) | 0.60 |
ALT > 40 U/L | 0.98 (0.96–1.01) | 0.07 | 0.99 (0.98–1.01) | 0.51 |
CHOL > 5.7 mmol/L | 0.89 (0.53–1.48) | 0.65 | 1.10 (0.59–2.06) | 0.77 |
Triglycerides > 1.7 mmol/L | 2.22 (0.61–8.08) | 0.23 | 1.56 (0.83–2.92) | 0.17 |
LDL-C > 3.4 mmol/L | 1.02 (0.50–2.09) | 0.96 | 1.40 (0.57–3.40) | 0.46 |
HOMA-IR > 2.5 | 1.12 (0.77–1.62) | 0.57 | 0.97 (0.46–2.05) | 0.95 |
Liver stiffness | 2.59 (1.21–5.54) | 0.014 | 1.52 (0.95–2.42) | 0.08 |
Liver fat content | 0.97 (0.90–1.05) | 0.52 | 1.52 (1.08–2.14) | 0.016 |
Pancreas fat content | 1.27 (0.75–2.17) | 0.37 | 1.05 (0.89–1.25) | 0.57 |
Alpha tocophereol | 1.62 (0.52–2.43) | 0.31 | 1.35 (0.92–1.94) | 0.15 |
PE (20:2/16:0) | 0.68 (0.45–0.98) | 0.038 | 1.26 (0.83–1.49) | 0.31 |
l-glutamine | 0.73 (0.29–1.83) | 0.50 | 1.03 (0.98–1.06) | 0.81 |
PC (18:2/20:2) | 0.59 (0.42–0.86) | 0.44 | 0.97 (0.89–1.05) | 0.89 |
SM (16:1/18:1) | 1.59 (0.58–2.69) | 0.22 | 0.79 (0.58–0.96) | 0.025 |
d-threitol | 1.22 (0.42–2.49) | 0.65 | 1.32 (0.73–2.63) | 0.62 |
PG (18:0/20:4) | 0.76 (0.58–0.92) | 0.019 | 2.02 (0.93–2.99) | 0.54 |
DNL (16:0/18:2n-6) | 2.42 (1.08–3.40) | 0.032 | 2.53 (1.23–3.98) | 0.020 |
Cystine | 0.68 (0.22–1.72) | 0.48 | 1.69 (1.44–1.93) | 0.008 |
l-leucine | 1.12 (0.92–1.24) | 0.53 | 1.55 (0.91–2.59) | 0.29 |